Expectedly, the PA-MSHA and Gefitinib combination resulted in increased caspase-3/caspase-9 cleavage and inhibition of EGFR-dependent activation of the AKT/ERK pathway involved in cancer cell survival [37]. The gene discussed is CASP9; the disease is cancer.